Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Plasma-Lyte 148 and Dextrose 5% is an intravenous solution that provides maintenance fluid, electrolytes, and calories. Dextrose provides energy and prevents ketosis. Plasma-Lyte 148 contains electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, gluconate) to replace losses and maintain acid-base balance.
ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.
For use as an intravenous source of water, electrolytes, and calories in patients who require fluid and electrolyte replacement and caloric intake,Off-label: treatment and prevention of hypovolemia, maintenance of fluid and electrolyte balance in perioperative settings
Maintenance of fluid and electrolyte balance in patients unable to take oral intake,Correction of metabolic acidosis when bicarbonate is contraindicated or not available,Replacement of electrolytes in hypokalemia, hyponatremia, hypomagnesemia, and hypocalcemia
IV infusion at a rate of 10-20 m L/kg/hour, not to exceed 100 m L/hour in adults without cardiac or renal compromise; adjust based on fluid status and serum electrolytes.
Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.
Not applicable as it is a balanced electrolyte solution with dextrose. Components distribute and are eliminated rapidly; dextrose half-life ~15-30 minutes in normoglycemia.
Not applicable as a single agent; components have variable half-lives (e.g., sodium and chloride distribute rapidly with an elimination half-life of 2-4 hours depending on renal function). In renal impairment, half-life may be prolonged.
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, producing energy. Acetate and gluconate are metabolized in the liver and tissues to bicarbonate. Electrolytes are not metabolized but are excreted or reutilized.
Acetate and gluconate are metabolized in the liver via the tricarboxylic acid cycle to bicarbonate; electrolytes are distributed in body fluids and excreted renally.
Components are excreted renally. Dextrose is metabolized; electrolytes are eliminated via kidneys (sodium, chloride, acetate, gluconate, magnesium, potassium). No biliary or fecal elimination.
Renal: >95% of administered electrolytes and water are excreted unchanged by the kidneys, primarily as urine. Biliary/fecal: <5% eliminated via feces, mainly unabsorbed components.
Electrolytes and dextrose have negligible protein binding (<1%). No significant binding.
Minimal to none: electrolytes like sodium, potassium, chloride, and bicarbonate are not protein-bound (<1%). Magnesium and calcium may have 30-50% binding to albumin, but overall negligible in solution.
Vd approximates extracellular fluid volume: ~0.15-0.25 L/kg for electrolyte components; dextrose distributes into total body water (~0.6 L/kg).
Distributes primarily into extracellular fluid (ECF) with Vd approximately 0.2 L/kg for sodium and chloride; calcium and magnesium distribute into a larger volume (0.5-0.6 L/kg) due to intracellular uptake.
Intravenous: 100% (by definition). Not administered via other routes.
Intravenous: 100% (complete systemic availability). Not administered orally or by other routes for systemic effect.
If GFR < 30 m L/min, reduce infusion rate by 50% and monitor potassium and phosphate levels closely; avoid in severe renal impairment if hyperkalemia or hyperphosphatemia is present.
Contraindicated in patients with severe renal impairment (GFR < 30 m L/min) due to risk of hyperkalemia. For GFR 30-50 m L/min, reduce infusion rate by 50% and monitor serum potassium closely. No adjustment needed for GFR > 50 m L/min.
No specific Child-Pugh-based adjustment required; use with caution in severe hepatic impairment due to risk of fluid overload and electrolyte disturbances.
Child-Pugh Class A: no adjustment. Class B: reduce infusion rate by 25% and monitor serum potassium. Class C: use with caution; consider alternative solutions due to risk of electrolyte imbalance.
Neonates and children: IV infusion at 5-10 m L/kg/hour, titrated to clinical need; maximum rate 20 m L/kg/hour; monitor electrolytes frequently.
Weight-based dosing: 20-30 m L/kg as a single intravenous infusion, administered at a rate not exceeding 5 m L/kg/hour. Maximum total volume: 1000 m L. Adjust based on clinical status and serum electrolytes.
Start at lower infusion rate (5-10 m L/kg/hour) due to age-related decline in renal function; reassess fluid status regularly to avoid volume overload.
Elderly patients may require reduced infusion rates (2-5 m L/min) due to decreased renal function and higher risk of fluid overload. Monitor serum potassium and renal function closely.
Not approved for use in patients with known hypersensitivity to any component. Not for use as a primary source of nutrition in neonates or low birth weight infants due to risk of aluminum toxicity.
None
Risk of fluid overload and electrolyte disturbances, especially in patients with renal impairment, heart failure, or severe dehydration,May cause hyperglycemia, particularly in diabetic patients,Monitor serum electrolytes, blood glucose, and fluid balance during infusion,Aluminum toxicity with prolonged use in renal impairment,Do not administer simultaneously with blood products through same IV line
Monitor serum electrolytes, fluid balance, and renal function regularly. Use with caution in patients with heart failure, renal impairment, or conditions predisposing to hypervolemia. Avoid rapid infusion; extravasation may cause tissue damage. Contains aluminum, which may accumulate in renal impairment.
Hypersensitivity to any component,Clinically significant hyperglycemia,Severe hyponatremia, hyperkalemia, or hypercalcemia,Patients with anuria or severe oliguria not due to hypovolemia
Hyperkalemia, hypernatremia, hypercalcemia, hypermagnesemia, severe metabolic alkalosis, severe renal failure with oliguria or anuria, and patients with a known hypersensitivity to any component.
No direct food interactions. However, dextrose content may affect blood glucose; patients with diabetes should monitor glucose levels closely and adjust insulin/oral hypoglycemic agents as directed. Use with caution in patients on sodium or potassium-modifying diets.
No direct food interactions; however, patients should avoid high-potassium foods (e.g., bananas, oranges, tomatoes) if hyperkalemia is a concern. Monitor dietary sodium and fluid intake as per clinical status.
Plasma-Lyte 148 and Dextrose 5% is an intravenous electrolyte and carbohydrate solution. At therapeutic doses, no direct fetal toxicity or teratogenicity is expected as electrolytes and dextrose are physiological substances. However, careful monitoring is required during pregnancy to avoid fluid overload, electrolyte imbalances, or hyperglycemia, which could indirectly affect fetal development. No specific trimester-specific risks are identified.
ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid administration may cause maternal fluid and electrolyte disturbances that can indirectly affect the fetus. Use with caution in the setting of impaired uteroplacental perfusion.
Plasma-Lyte 148 and Dextrose 5% is compatible with breastfeeding. Electrolytes and dextrose are normal blood components that are transferred into breast milk in small amounts, not expected to cause adverse effects in the infant. M/P ratio is not applicable as it is a mixture of physiological substances.
ISOLYTE E is compatible with breastfeeding. Electrolytes are normally present in breast milk; exogenous administration does not significantly alter infant exposure. M/P ratio not applicable as drug is not a xenobiotic.
Pharmacokinetic changes during pregnancy (increased plasma volume, altered renal function) may require adjustments in infusion rate and total volume to maintain electrolyte and glucose homeostasis. Dose should be individualized based on maternal weight, clinical status, and laboratory values; no fixed dose adjustment is required.
No dose adjustment is required for pregnancy. However, pregnant patients may have increased plasma volume and altered renal function; infusion rates should be individualized based on clinical status and serum electrolyte monitoring. Rapid correction of electrolyte imbalances should be avoided to prevent fetal osmotic shifts.
PLASMA-LYTE 148 and Dextrose 5% is an isotonic solution containing electrolytes and dextrose. Use within 24 hours of spiking the container. Avoid administering through the same line as blood products due to risk of hemolysis from electrolyte content. Monitor serum glucose, electrolytes, and fluid balance, especially in patients with impaired renal function, diabetes, or heart failure. The solution has a p H of ~5.5; consider compatibility with co-administered drugs.
ISOLYTE E is a balanced electrolyte solution with 5% dextrose, used for maintenance fluid therapy. Monitor serum potassium closely in renal impairment; contains 20 m Eq/L potassium. Caution in patients with hyperkalemia, renal failure, or metabolic alkalosis. Do not administer simultaneously with blood products due to risk of hemolysis. Observe for signs of fluid overload in patients with heart failure.
This solution provides fluids and sugar to help maintain hydration and energy.,Tell your healthcare provider if you have diabetes, heart problems, or kidney disease.,You may experience swelling, shortness of breath, or changes in urination; report these immediately.,Your blood sugar and electrolyte levels will be monitored during treatment.,Do not use this solution if it is cloudy, discolored, or contains particles.
This solution is used to replace fluids and electrolytes and provide calories. Tell your doctor if you have kidney problems, heart disease, or are on a low-potassium diet. Report any swelling, shortness of breath, or irregular heartbeat. Do not take over-the-counter potassium supplements without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E IN PLASTIC CONTAINER, answered by our medical review team.
PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Plasma-Lyte 148 and Dextrose 5% is an intravenous solution that provides maintenance fluid, electrolytes, and calories. Dextrose provides energy and prevents ketosis. Plasma-Lyte 148 contains electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, gluconate) to replace losses and maintain acid-base balance.. ISOLYTE E IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Intravenous Electrolyte Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER is: IV infusion at a rate of 10-20 m L/kg/hour, not to exceed 100 m L/hour in adults without cardiac or renal compromise; adjust based on fluid status and serum electrolytes.. The standard adult dose of ISOLYTE E IN PLASTIC CONTAINER is: Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Plasma-Lyte 148 and Dextrose 5% is an intravenous electrolyte and carbohydrate solution. At therapeutic doses, no direct fetal toxicity or teratogenicity is expected as electrolyte. ISOLYTE E IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid ad. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.